HealZen/SIMM Announce Global License and Strategic Collaboration to Advance BTK Degrader
TIME:
Jan 10,2025
Collaboration to advance investigational BTK degrader co-developed by HealZen and SIMM
Hangzhou, China - January 10, 2025 - Hangzhou HealZen Therapeutics (“HealZen”) and Shanghai Institute of Materia Medica, Chinese Academy of Sciences (“SIMM”), jointly announced today it has entered into a global license agreement with Johnson & Johnson* to develop potential best-in-class BTK degraders for the treatment of multiple diseases.
"We’re delighted to enter into this agreement with Johnson & Johnson to accelerate the development of our BTK degrader," stated Xinglu Zhou, CEO and Co-founder of HealZen. “We remain committed in our mission of rapidly delivering innovative therapies and new treatment options for patients with hard-to-treat diseases."
* Legal entity, Janssen Pharmaceutica NV
About Hangzhou HealZen Therapeutics Co., Ltd.
HealZen is a leading clinical-stage biotechnology company focused on the discovery and development of novel therapies based on our proprietary technology platform. We are dedicated to develop differentiated novel treatment approaches by targeting previously undruggable proteins for potential treatment of various human disease such as cancer, autoimmune diseases and CNS disorders.
About Shanghai Institute of Materia Medica, Chinese Academy of Sciences
Founded in 1932, SIMM has the longest history as a comprehensive research institution for drug discovery in China. In line with frontiers in life sciences and aiming at solving key scientific problems in drug discovery, SIMM carries out both basic and applied studies and develops new theories, methods and technologies. Research priorities are given to treat major diseases, such as cancer, cardio-cerebrovascular disease, neuropsychiatric disease, metabolic disease, autoimmune disease, and infectious disease. SIMM is also exploring the development of modern Traditional Chinese Medicine.
For more information about HealZen, please visit http://www.healzentx.com/
Contact: info@healzentx.com
For more information about SIMM, please visit http://www.simm.ac.cn/
Related News
Jan 10,2025
HealZen/SIMM Announce Global License and Strategic Collaboration to Advance BTK Degrader
Jun 19,2024
The innovative drug HZ-H08905 tablets of Hangzhou HealZen Therapeutics Co., Ltd has been approved for a pivotal Phase III clinical trial for the treatment of recurrent or refractory peripheral T-cell lymphoma
Hangzhou HealZen Therapeutics Co., Ltd recently announced that its independently developed Class 1 innovative drug, HZ-H08905 (CK1ε&PI3Kδ dual-target inhibitor), has been officially approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA), China, to conduct a pivotal registration Phase III clinical trial for the treatment of recurrent or refractory peripheral T-cell lymphoma (R/R PTCL).
HealZen Therapeutics Co., Ltd.
Telephone: +86-571-86933001
E-mail: info@healzentx.com
Address: 8th Floor, Building 16, Hexiang Science and Technology Center, Qiantang District, Hangzhou City, P.R.China
Copyright © HealZen Therapeutics Co., Ltd. Powered by www.300.cn